Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus strain H5N1 clade 1 vaccine - Sanofi

Drug Profile

Influenza virus strain H5N1 clade 1 vaccine - Sanofi

Alternative Names: AF 03; Avian influenza (bird flu) virus vaccine - Sanofi/NIAID; Emerflu; H5N1 influenza vaccine - sanofi; H5N1 split antigen influenza vaccine Alum adjuvanted - sanofi; Low-dose H5N1 vaccine - sanofi; Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 (NIBRG-14) - sanofi; Pandemic influenza vaccine - sanofi

Latest Information Update: 04 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi; sanofi pasteur
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus H5N1 subtype

Most Recent Events

  • 29 Nov 2017 Sanofi Pasteur's influenza virus strain H5N1 clade 1 vaccine is registered in USA and Australia and will not be sold commercially
  • 20 Mar 2015 The vaccine is approved in USA and Australia for Influenza A virus H5n1 subtype (Prevention)
  • 20 Mar 2015 No recent reports on development identified - Phase-II for Influenza-A virus H5N1 subtype (In children, Prevention) in Thailand (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top